Results 141 to 150 of about 7,917 (182)
BACKGROUND: Vigabatrin is a newly licensed drug for use in patients with epilepsy. We investigated whether this drug was comparable to standard first-line monotherapy in efficacy and incidence of adverse events.
David Chadwick
exaly +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Seminars in Pediatric Neurology, 1997
Vigabatrin is a structural analogue of gamma amino butyric acid (GABA), which binds irreversibly to GABA-transaminase causing increased brain levels of GABA. It is an important advance in the medical management of children with epilepsy. It appears to be particularly effective in the treatment of infantile spasms, especially when caused by tuberous ...
W D, Shields, R, Sankar
+5 more sources
Vigabatrin is a structural analogue of gamma amino butyric acid (GABA), which binds irreversibly to GABA-transaminase causing increased brain levels of GABA. It is an important advance in the medical management of children with epilepsy. It appears to be particularly effective in the treatment of infantile spasms, especially when caused by tuberous ...
W D, Shields, R, Sankar
+5 more sources
Epilepsia, 1994
Summary: The discovery of γ‐aminobutyric acid (GABA) as the first major inhibitory neurotransmitter and a program exploring the use of enzyme inhibition as a therapeutic tool provided the basis for the conception of vigabatrin (VGB, Sabril). This molecule, an analogue of GABA, has a highly specific activity as an enzyme‐activated irreversible ...
J P, Mumford, D J, Cannon
+5 more sources
Summary: The discovery of γ‐aminobutyric acid (GABA) as the first major inhibitory neurotransmitter and a program exploring the use of enzyme inhibition as a therapeutic tool provided the basis for the conception of vigabatrin (VGB, Sabril). This molecule, an analogue of GABA, has a highly specific activity as an enzyme‐activated irreversible ...
J P, Mumford, D J, Cannon
+5 more sources
Annals of Pharmacotherapy, 1993
Objective To introduce the reader to the use of a new agent, vigabatrin, in the treatment of refractory complex partial seizures. Clinical trials and pharmacokinetic data are reviewed, as well as neuropathology, adverse effects, drug interactions, and dosage guidelines.
openaire +3 more sources
Objective To introduce the reader to the use of a new agent, vigabatrin, in the treatment of refractory complex partial seizures. Clinical trials and pharmacokinetic data are reviewed, as well as neuropathology, adverse effects, drug interactions, and dosage guidelines.
openaire +3 more sources
Clinical Pharmacokinetics, 1992
Vigabatrin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is supplied as a racemic mixture, with the S(+) enantiomer possessing pharmacological activity. [R,S]-Vigabatrin plasma concentrations can be estimated using high-performance liquid chromatographic methods. Only gas chromatography-mass spectrometry
E, Rey, G, Pons, G, Olive
openaire +2 more sources
Vigabatrin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is supplied as a racemic mixture, with the S(+) enantiomer possessing pharmacological activity. [R,S]-Vigabatrin plasma concentrations can be estimated using high-performance liquid chromatographic methods. Only gas chromatography-mass spectrometry
E, Rey, G, Pons, G, Olive
openaire +2 more sources
Pharmacology & Toxicology, 1992
Abstract: Vigabatrin (gamma‐vinyl GABA) is a relatively new antiepileptic drug. Vigabatrin increases the concentration of gamma‐aminobutyric acid (GABA) in the brain by inhibiting the major GABA metabolizing enzyme, GABA transaminase. Controlled clinical trials have demonstrated an excellent antiepileptic effect of vigabatrin, especially in the ...
A, Sabers, L, Gram
openaire +2 more sources
Abstract: Vigabatrin (gamma‐vinyl GABA) is a relatively new antiepileptic drug. Vigabatrin increases the concentration of gamma‐aminobutyric acid (GABA) in the brain by inhibiting the major GABA metabolizing enzyme, GABA transaminase. Controlled clinical trials have demonstrated an excellent antiepileptic effect of vigabatrin, especially in the ...
A, Sabers, L, Gram
openaire +2 more sources
Epilepsia, 1995
Summary: γ‐Aminobutyric acid (GABA) was first proposed as a putative inhibitory neurotransmitter by Elliot and van Gelder in 1958. Since then, numerous efforts have been made to find ways to increase GABA at its receptor sites, based on the findings that decreased GABA results in convulsions in animals and that agents enhancing GABA‐mediated functions
openaire +2 more sources
Summary: γ‐Aminobutyric acid (GABA) was first proposed as a putative inhibitory neurotransmitter by Elliot and van Gelder in 1958. Since then, numerous efforts have been made to find ways to increase GABA at its receptor sites, based on the findings that decreased GABA results in convulsions in animals and that agents enhancing GABA‐mediated functions
openaire +2 more sources
The Neuropathology of Vigabatrin
Epilepsia, 1989Summary: Vigabatrin (gamma vinyl GABA, GVG), an enzyme‐activated, irreversible inhibitor of GABA transaminase, was administered orally to rats, dogs, and monkeys to observe toxicologic reactions. Myelin vacuolation of the brain was observed. The vacuolation was limited to myelinated tracts and resulted from separation of the myelin sheath at the ...
openaire +2 more sources

